In this study, we administered the CIS in healthy participants across hunger and satiety states together with assays of circulating levels of insulin, leptin, and liver-expressed antimicrobial peptide 2 (LEAP-2), which is an antagonist of ghrelin action that is elevated by calorie consumption signaling satiety [17]. This evidence concerns the gene LEAP2 and in situ carcinoma.